These findings point to a previously unrecognized role for Egr-1 in the pathogenesis of SSc, and raise the possibility that blocking excessive Egr-1 signaling might be a potential therapeutic strategy to control fibrosis. Here, EGR1 is linked to systemic sclerosis.